Diabetes Patients With High Triglycerides and Low HDL Cholesterol get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study

SYDNEY--27 Feb--PRNewswire-AsiaNet/InfoQuest Fenofibrate treatment reduces cardiovascular disease (CVD) risk (defined by total cardiovascular events: the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularization) in patients with type 2 diabetes and atherogenic dyslipidemia, that is, the combination of high triglyceride (2.3 mmol/L-200mg/dL or higher) and low high-density lipoprotein (HDL) cholesterol (

---